Long‐Term Neurologic Exam Findings in People Diagnosed and Treated During Acute HIV Infection
ABSTRACT Objective Evaluate clinical and laboratory correlates of abnormal neurologic exam findings after acute HIV infection (AHI). Methods Participants from the RV254/SEARCH 010 cohort in Bangkok underwent standardized neurologic examinations at Weeks 0 (AHI), 12, 96, and 288 following antiretroviral therapy (ART).
Kathryn B. Holroyd +118 more
wiley +1 more source
Personalizing HIV therapy, mission impossible? [PDF]
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core +1 more source
Telomerase is a specialized reverse transcriptase responsible for the de novo synthesis of telomeric DNA repeats. In addition to its established reverse transcriptase and terminal transferase activities, recent reports have revealed unexpected cellular ...
Kyle R Hukezalie +3 more
doaj +1 more source
Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. [PDF]
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Boujamline S +11 more
europepmc +2 more sources
Murine leukemia virus reverse transcriptase: Structural comparison with HIV-1 reverse transcriptase [PDF]
Recent X-ray crystal structure determinations of Moloney murine leukemia virus reverse transcriptase (MoMLV RT) have allowed for more accurate structure/function comparisons to HIV-1 RT than were formerly possible. Previous biochemical studies of MoMLV RT in conjunction with knowledge of sequence homologies to HIV-1 RT and overall fold similarities to ...
Marie L, Coté, Monica J, Roth
openaire +2 more sources
Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu +7 more
wiley +1 more source
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? [PDF]
Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic complications, have emerged as important long-term toxicities associated with antiretroviral therapy in the current era. The wealth of data that has accumulated over
Nolan, D.
core
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis [PDF]
Includes bibliographical references.Sub-Saharan Africa is overwhelmed by dual epidemics of human immunodeficiency virus (HIV) and tuberculosis (TB) infection.
Cohen, Karen
core +1 more source
Modulation of miR‐23b Wnt/β‐catenin Axis Strengthens Endothelial Barrier Properties
Early blood‐brain barrier (BBB) disruption contributes to stroke and CNS disease pathology. miR‐23b was identified as a regulator of BBB integrity in brain endothelial cells. Inhibition of miR‐23b enhanced barrier‐associated properties, promoted repair‐related signaling, and reduced BBB leakage in experimental stroke models, supporting further ...
Victor Anthony Martinez +16 more
wiley +1 more source
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads [PDF]
Background. Our objective was to compare the rate of viral rebound and therapy failure in patients receiving abacavir or efavirenz as the third drug ( in addition to 2 non-abacavir nucleosides) in combination antiretroviral therapy ( cART) and to compare
Phillips, AN +44 more
core +1 more source

